Immunic (in discussions with Roche) plans to conduct FDA regulatory meetings for two...
Unlearn.AI enhances Alzheimer’s drug through machine learning
First machine-learning (ML) platform developer Unlearn.AI has reported that its machine learning (ML) platform is capable of providing digital patient records designed to supplement actual control patients in clinical trials of Alzheimer’s disease.
Biohaven to continue testing troriluzole in Alzheimer’s patients
Biohaven Pharmaceutical has received notification from the independent Data Safety Monitoring Board (DSMB) to continue its Phase II/III T2 Protect AD study of troriluzole for the treatment of mild-to-moderate Alzheimer's disease.
Sage Therapeutics’ SAGE-217 fails in late-stage depression trial
Top-line data from Sage Therapeutics’ Phase III MOUNTAIN clinical trial have shown that SAGE-217 failed to meet the primary endpoint in adults with major depressive disorder (MDD).
Cerevance begins Phase II trial to treat Parkinson’s
Biopharmaceutical firm Cerevance has commenced a Phase II clinical trial of its small molecule drug, CVN424, to potentially treat patients with Parkinson’s disease.
Acadia’s drug cuts psychosis relapse risk in dementia patients
Acadia Pharmaceuticals has reported that pimavanserin reduced the risk of psychosis relapse in dementia patients who participated in its Phase III HARMONY clinical trial.
Immunic in talks with Roche for Ocrevus use in planned Phase II/III multiple sclerosis combination
Immunic (in discussions with Roche) plans to conduct FDA regulatory meetings for two trials sometime in mid-2020.
PPD expands early development research capabilities
Global contract research organisation PPD has added significant neuroscience and ethno-bridging expertise, expanding its early development research services for its clinical research units (CRUs).
INmune Bio starts dosing Alzheimer’s patients in Phase Ib trial
INmune Bio has commenced the dosing of patients in a Phase Ib clinical trial of XPro1595 being conducted to help treat Alzheimer's disease.
VUMERITY (diroximel fumarate) for the Treatment of Multiple Sclerosis
VUMERITY™ (diroximel fumarate), previously known as ALKS 8700, is a novel oral formulation indicated for the treatment of relapsing forms of multiple sclerosis (MS).